Calcitonin nasal spray and increased cancer risk: A population-based nested case-control study

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 11, 2014, Pages 4259-4264

  Sun, Li Min ^a   Lin, Ming Chia ^b   Muo, Chih Hsin ^c   Liang, Ji An ^d,e   Kao, Chia Hung ^d,e  

^a KAOHSIUNG ARMED FORCES GENERAL HOSPITAL   (Taiwan)

^b E DA HOSPITAL   (Taiwan)

^c Management Office for Health Data   (Taiwan)

^d School of Chinese Medicine   (Taiwan)

^e CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; NOSE SPRAY; BONE DENSITY CONSERVATION AGENT;

AGED; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER RISK; COHORT ANALYSIS; COLORECTAL CANCER; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA BASE; DRUG USE; FEMALE; HEAD AND NECK CANCER; HUMAN; LIVER CANCER; LOGISTIC REGRESSION ANALYSIS; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; PROSTATE CANCER; TAIWAN; BREAST NEOPLASMS; CASE CONTROL STUDY; CHEMICALLY INDUCED; EPIDEMIOLOGY; FACTUAL DATABASE; INCIDENCE; LIVER NEOPLASMS; MIDDLE AGED; RISK; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; BREAST NEOPLASMS; CALCITONIN; CASE-CONTROL STUDIES; DATABASES, FACTUAL; FEMALE; HUMANS; INCIDENCE; LIVER NEOPLASMS; MALE; MIDDLE AGED; NASAL SPRAYS; OSTEOPOROSIS; RISK; TAIWAN;

EID: 84910016491     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-2239     Document Type: Article

References (33)

1. Wall GC, Heyneman CA. Calcitonin in phantom limb pain. Ann Pharmacother. 1999; 33: 499-501.
2. Calcitonin. Wikipedia website. http://en.wikipedia.org/wiki/Calcitonin. Accessed May 3, 2014.
3. Arnala IO. Salmon calcitonin (Miacalcic ns 200 IU) in prevention of bone loss after hip replacement. Scand J Surg. 2012; 101: 249-254.
4. Traynor K. Experts recommend against calcitonin-salmon for postmenopausal osteoporosis. Am J Health Syst Pharm. 2013; 70: 648-650.
5. In brief: cancer risk with salmon calcitonin. Med Lett Drugs Ther. 2013; 55: 29.
6. Drugs for postmenopausal osteoporosis. Treat Guidel Med Lett. 2011; 9: 67.
7. Novartis. FDA Joint Reproductive Health Drugs and Drug Safety and Risk Management Advisory Committee meeting on the benefit/ risk of salmon calcitonin for the treatment of postmenopausal osteoporosis. Briefing book. Available at http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM341781.pdf. Accessed May 3, 2014.
8. Overman RA, Borse M, Gourlay ML. Salmon calcitonin use and associated cancer risk. Ann Pharmacother. 2013; 47: 1675-1684.
9. Synthetic calcitonin (salmon) nasal spray (NS): market withdrawal of all products, effective October 1st, 2013-for health professionals. Health Canada website. http://healthycanadians.gc.ca/recall-alertrappel-avis/hc-sc/2013/34783a-eng.php. Accessed May 3, 2014.
10. Evaluation the effectiveness and safety of calcitonin from Taiwan Food and Drug Administration. Food and Drug Administration website.http://www.fda.gov.tw/tc/newsContent.aspx?id-10532&chk-0f750100-b752-4bf0-b686-9f177c72fd37¶m-pn%3d32%26cid%3d3%26cchk%3d46552e96-810a-42c3-83e1-bd5e42344633#.U-v6GaNyyQA. Accessed May 3, 2014.
11. Taiwan National Health Insurance program. National Health Insurance Administration Ministry of Health and Welfare website. http://www.nhi.gov.tw/english/index.aspx. Accessed May 3, 2014.
12. Liang JA, Sun LM, Lin MC, et al. A population-based nested casecontrol study in Taiwan: use of 5-reductase inhibitors did not decrease prostate cancer risk in patients with benign prostate hyperplasia. Oncologist. 2012; 17: 986-991.
13. Inoue D, Shih C, Galson DL, Goldring SR, Horne WC, Baron R. Calcitonin-dependent down-regulation of the mouse C1a calcitonin receptor in cells of the osteoclast lineage involves a transcriptional mechanism. Endocrinology. 1999; 140: 1060-1068.
14. Mechanism of action of salmon calcitonin. DrugBank website. http://www.drugbank.ca/drugs/DB00017. Accessed May 3, 2014.
15. Plosker GL, McTavish D. Intranasal salcatonin (salmon calcitonin). A review of its pharmacological properties and role in the management of postmenopausal osteoporosis. Drugs Aging. 1996; 8: 378-400.
16. Muñoz-Torres M, Alonso G, Raya MP. Calcitonin therapy in osteoporosis. Treat Endocrinol. 2004; 3: 117-132.
17. Side effects of Miacalcin. RxList website. http://www.rxlist.com/miacalcin-drug/side-effects-interactions.htm. Accessed May 3, 2014.
18. Lee WY, Sun LM, Lin MC, et al. Ahigher dosage of oral alendronate will increase the subsequent cancer risk of osteoporosis patients in Taiwan: a population-based cohort study. PLoS One. 2012; 7: e53032.
19. Green J, Czanner G, Reeves G, Watson J, Wise L, Beral V. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. BMJ. 2010; 341: c4444.
20. Newcomb PA, Trentham-Dietz A, Hampton JM. Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk. Br J Cancer. 2010; 102: 799-802.
21. CawthonPM.Gender differences in osteoporosis and fractures. Clin Orthop Relat Res. 2011; 469: 1900-1905.
22. Scarpace PJ, Neuman WF, Raisz LG. Metabolism of radioiodinated salmon calcitonin in rats. Endocrinology. 1977; 100: 1260-1267.
23. Blower PJ, Puncher MR, Kettle AG, et al. Iodine-123 salmon calcitonin, an imaging agent for calcitonin receptors: synthesis, biodistribution, metabolism and dosimetry in humans. Eur J NuclMed. 1998; 25: 101-108.
24. Godinho AF, Cavalcante GJ, Machado MG, et al. Effect of calcitonin on hepatic drug metabolism. Braz J Med Biol Res. 1988; 21: 851-853.
25. Wang D, Vélez de-la-Paz OI, Zhai JX, Liu DW. Serum 25-hydroxyvitamin D and breast cancer risk: a meta-analysis of prospective studies. Tumour Biol. 2013; 34: 3509-3517.
26. Abbas S, Linseisen J, Slanger T, et al. Serum 25-hydroxyvitamin D and risk of post-menopausal breast cancer-results of a large casecontrol study. Carcinogenesis. 2008; 29: 93-99.
27. Bertone-Johnson ER, Chen WY, Holick MF, et al. Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of breast cancer. Cancer Epidemiol Biomarkers Prev. 2005; 14: 1991-1997.
28. Ng KW, Livesey SA, Larkins RG, Martin TJ. Calcitonin effects on growth and on selective activation of type II isoenzyme of cyclic adenosine 3′: 5′-monophosphate-dependent proteinkinase in T 47D human breast cancer cells. Cancer Res. 1983; 43: 794-800.
29. Marjoribanks J, Farquhar C, Roberts H, Lethaby A. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev. 2012; 7: CD004143.
30. Anderson GL, Chlebowski RT, Aragaki AK, et al. Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncol. 2012; 13: 476-486.
31. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med. 2000; 342: 1887-1892.
32. Schwarz S, Messerschmidt H, Doren M. Psychosocial risk factors for cancer development. Med Klin (Munich). 2007; 102: 967-979.
33. ChesnutCH3rd, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The Prevent Recurrence of Osteoporotic Fractures study. PROOF study group. Am J Med. 2000; 109: 267-276.